COVID19 (disease) – Page 4 – Talk Bio

Actionable Insights Powered by AI

Pfizer’s R&D Chief Mikael Dolsten to Step Down After 15 Years of Leadership

10 months ago talkbio0Tagged COVID19 (disease), development aspects, Mikael, Pfizer, research, Scientific Officer, Successor Search, Vaccines

Pfizer, Mikael Dolsten, Chief Scientific Officer, Research and Development, COVID-19 Vaccine, Successor Search

Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial

11 months ago talkbio0Tagged COVID19 (disease), Immune response, Late-Stage Trial, Moderna, Respiratory viruses, SARS-CoV-2, Vaccines, Vaccines, Combined

Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses

FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product

11 months ago talkbio0Tagged Approved, COVID19 (disease), Moderna, mRESVIA, Respiratory syncytial virus, RNA, Messenger, Spikevax, United States Food and Drug Administration, Vaccines

Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA

Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine

12 months ago talkbio0Tagged BioNTech, COVID19 (disease), Drug Industry, EPO, EU, European (ethnic group), Intellectual Property, Legal patent, Moderna, mRNA technology, Pfizer, Vaccines

Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.

AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals

12 months ago talkbio0Tagged Antibodies, AstraZeneca, Clinical Trials, COVID19 (disease), Enhance (action), Immune response, Immunocompromised Host, individuals, Monoclonal Antibodies, Neutralization (Chemistry), Protection, Virus

AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.

AstraZeneca’s Next-Generation Covid Therapy Shines in Phase 3 Trials

12 months ago talkbio0Tagged Antibodies, AstraZeneca, COVID19 (disease), Effectiveness, Evusheld, next-generation therapy, Phase 3 trials, Safety, successor

AstraZeneca, Covid-19, Evusheld, Phase 3 trials, next-generation therapy, successor, antibody treatment, prevention, efficacy, safety.

Europe Temporarily Halts AstraZeneca’s Vaxzevria COVID-19 Vaccine on Company’s Request

1 year ago talkbio0Tagged AstraZeneca, authorization, concerns, COVID19 (disease), Europe, European Medicines Agency, Pharmacovigilance, Safety, Suspensions, Vaccines, Vaxzevria

AstraZeneca, Vaxzevria, COVID-19 vaccine, marketing authorization, suspension, Europe, European Medicines Agency (EMA), pharmacovigilance, safety concerns.

Pharmaceutical Industry’s Public Image Deteriorates Post-Pandemic Era

1 year ago talkbio0Tagged COVID19 (disease), development aspects, Drug Industry, Pandemics, Public Opinion, reputation, Translucent, Vaccines

Pharmaceutical industry, reputation, pandemic, public opinion, COVID-19, vaccine development, drug pricing, transparency.

GSK’s Vaccine Sales Surge Continues, Boosting 2024 Outlook

1 year ago talkbio0Tagged 2024, COVID19 (disease), Drug Industry, Health Care Sector, Projections and Predictions, revenue growth, Shingrix, SmithKline Beecham, SmithKline Beecham, Vaccines

GSK, GlaxoSmithKline, vaccine sales, 2024 forecasts, pharmaceutical industry, revenue growth, COVID-19 vaccines, Shingrix, healthcare sector

GSK Files Lawsuit Against Pfizer and BioNTech for Alleged COVID-19 Vaccine Patent Violation

1 year ago talkbio0Tagged BioNTech, COVID19 (disease), infringement, Intellectual Property, Legal patent, Pfizer, SmithKline Beecham, Vaccines

GSK, Pfizer, BioNTech, COVID-19, patent infringement, vaccine, lawsuit, intellectual property